Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27793766 | 0.71 | — | — | |
| SCHEMBL17728586 | 0.67 | MAPT (0.39) | ALDH1A1MAPTSRD5A1 | |
| SCHEMBL17728540 | 0.63 | NOTUM (0.35) | NOTUMKEAP1CYP1A2CYP2C9CHRNB2 | |
| SCHEMBL17728629 | 0.63 | NOTUM (0.35) | NOTUMCYP17A1KEAP1CYP1A2CYP2C9 | |
| SCHEMBL3148924 | 0.63 | NOTUM (0.34) | NOTUMMAP3K5KEAP1 | |
| SCHEMBL28780246 | 0.63 | NOTUM (0.41) | NOTUMKEAP1CYP1A2CYP2C9CHRNB2 | |
| SCHEMBL24240280 | 0.61 | NOTUM (0.48) | NOTUMMAP3K5KEAP1CYP1A2CYP2C9 | |
| SCHEMBL10447781 | 0.60 | NOTUM (0.78) | NOTUMKEAP1 | |
| SCHEMBL6129230 | 0.60 | ALDH1A1 (0.68) | ALDH1A1MAPTSRD5A1 | |
| SCHEMBL3148920 | 0.59 | NOTUM (0.34) | NOTUMCYP17A1MAP3K5KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890139-B2 | CYP17 inhibitors/antiandrogens | ORION CORPORATION (FI) | 2018-02-13 | — | — | US | disclosed |
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | ORION CORPORATION (FI) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130254-A1 | NOVEL CYP17 INHIBITORS/ANTIANDROGENS | CYP17A1, CYP19A1, CYP21A2 | NOTUM 299/4885CYP17A1 1/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.